MBX Biosciences (MBX) Is Up 84.0% After Positive Phase 2 Results for Canvuparatide - Has The Bull Case Changed? [Yahoo! Finance]
MBX Biosciences, Inc. (MBX)
Company Research
Source: Yahoo! Finance
achieving the primary endpoint with statistical significance and a high responder rate at 6 months in adults with chronic hypoparathyroidism. An impressive 94% of patients who completed the study chose to enter the open-label extension, highlighting ongoing patient engagement and interest in the therapy's long-term potential. We'll explore how the advancement to a Phase 3 trial for canvuparatide factors into MBX Biosciences' evolving investment narrative. Uncover the next big thing with financially sound penny stocks that balance risk and reward What Is MBX Biosciences' Investment Narrative? For shareholders of MBX Biosciences, the big picture focuses on believing in the company's ability to transition promising clinical results, like the recent Phase 2 win for canvuparatide, into an eventual commercial product. The strong efficacy and patient retention reported in the latest trial are likely to be a meaningful short-term catalyst, boosting optimism ahead of the planned Phas
Show less
Read more
Impact Snapshot
Event Time:
MBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBX alerts
High impacting MBX Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
MBX
News
- MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM Exit - What's Changed [Yahoo! Finance]Yahoo! Finance
- MBX Biosciences (NASDAQ:MBX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "sell" rating and a $18.00 price target on the stock.MarketBeat
- Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus [Yahoo! Finance]Yahoo! Finance
- How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% [Yahoo! Finance]Yahoo! Finance
- This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones [Yahoo! Finance]Yahoo! Finance
MBX
Earnings
- 11/6/25 - Beat
MBX
Sec Filings
- 11/25/25 - Form 4
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- MBX's page on the SEC website